Anyone following how public humanoid-adjacent stocks have actually performed this year?

[pierregreen]

Just to be precise about one thing: A recurring critique worth taking seriously: a lot of publicly announced 'production capacity' targets (100k units/year, 1 million/year by 2028, etc.) are aspirational manufacturing targets, not confirmed sales or deployment numbers, and the gap between the two has historically been large in hardware industries.

[thomas65]

@pierregreen I dealt with almost this exact situation. Chinese humanoid startups reportedly accounted for around 65% of deal volume in 2025, while US companies still won the largest individual rounds, with at least three raises exceeding $400 million - deal count and deal size tell different stories depending on which region you're looking at. Totally unrelated but has anyone else noticed how fast component costs are dropping this year.

[green28]

@thomas65 Genuinely curious - Q1 2026 alone saw about $2.37 billion raised across 11 rounds, compared to roughly $611 million across 9 rounds in the same quarter of 2025 - both deal size and deal count are climbing, not just one or the other.

[lukas.singh1]

+1 to this. Worth adding: This hype cycle differs from earlier robotics hype waves mainly in having real, verifiable revenue-generating deployments (BMW's Figure line, Amazon's Digit units) alongside the speculative funding activity - previous waves were almost entirely research-and-demo-stage without production deployments at this scale.

[karentaylor]

Worth being a little skeptical of the marketing angle here. Global humanoid robotics funding reached roughly $8.6 billion across about 113 rounds by early 2026, with 2026 year-to-date funding already exceeding all of 2025's total - a clear acceleration in capital flowing into the sector. Insurance and liability frameworks for humanoids working directly around people are still immature in most jurisdictions, which is a real, under-discussed constraint on deployment speed that gets far less attention than the flashier technology headlines.

[carter42]

Speaking from personal experience here, Unit economics for an early fleet deployment have to include maintenance, downtime, and technician support costs, not just the sticker price of the robot - a lower unit price (like Unitree's roughly $16k G1) doesn't automatically mean a lower total cost of ownership if support infrastructure is thinner. Q1 2026 alone saw about $2.37 billion raised across 11 rounds, compared to roughly $611 million across 9 rounds in the same quarter of 2025 - both deal size and deal count are climbing, not just one or the other.

[joseph_sing]

This is a great summary, thanks. Self-reported deployment and uptime numbers from humanoid companies are inherently hard to independently verify, since there's no standardized, third-party reporting requirement yet - a healthy dose of skepticism toward company press releases is reasonable until independent data catches up. Totally unrelated but has anyone else noticed how fast component costs are dropping this year.

[chenperez]

@joseph_sing Short answer: The market consolidation question (which of the 100+ companies chasing this space survive) is complicated by the fact that hardware is genuinely capital-intensive to scale, so smaller players without a clear cost or technology moat are structurally at risk once the well-funded leaders reach real manufacturing scale.

[ssantos]

@chenperez Speaking from personal experience here, Unit economics for an early fleet deployment have to include maintenance, downtime, and technician support costs, not just the sticker price of the robot - a lower unit price (like Unitree's roughly $16k G1) doesn't automatically mean a lower total cost of ownership if support infrastructure is thinner.

[servoken70]

@ssantos Slight correction, though the overall point stands: Robotics-as-a-Service (RaaS) - subscription, leasing, or usage-based pricing instead of outright purchase - is emerging specifically to lower the adoption barrier for businesses that don't want to commit large capital expenditure to an unproven new category.